Aspartate Aminotransferase

Aspartate Aminotransferase, commonly abbreviated AST, is a biomarker categorized as liver-related. It is reported as a laboratory result using a defined measurement unit, identifying which marker is being assessed.

Aspartate Aminotransferase is measured from a serum sample, meaning the test uses the liquid portion of a blood sample. Fasting is not required, so the collection can be arranged without fasting unless the clinician or laboratory has given other instructions for tests being performed at the same time.

The result is reported in U/L and should be read against the reference range shown with the test. The comparison range differs by sex, so the applicable range matters when reviewing the result. An optimal range is also displayed separately; it is narrower than the reference range and provides additional context rather than replacing the laboratory reference range.

For this biomarker, lower values are considered preferable within the ranges shown. A result is best interpreted in context rather than in isolation, particularly when reviewing related markers such as Alt, Ggt, and Ck. When arranging testing or discussing an unexpected result, a clinician can help determine how the result fits with the reason for testing and any other laboratory findings.

Aspartate Aminotransferase is reported from a serum sample in U/L. Its reference range describes the interval used to distinguish results that fall within the laboratory’s usual range, while the optimal range is a narrower interval within that broader range. Because lower values are considered better for this biomarker, a result can be inside the reference range without being inside the tighter optimal range.

Interpret a number against the reference range printed on the same report. Laboratories may use different ranges or units, and the applicable interval can also vary by sex, so comparisons with another report may be misleading. Fasting is not required for this measurement, although the sample type and testing context remain relevant when a clinician reviews the result.

A single value is not a diagnosis and does not, by itself, establish that something is wrong. Results outside the printed reference range should be discussed with a clinician, who can interpret them alongside the broader clinical picture.

Because lower AST is the favorable direction, the interventions directly measured against this marker were grouped mainly toward decreases. These included Milk Thistle (Silymarin), Vitamin E, Omega-3, Reishi, Astragalus, Chlorella, Coenzyme Q10, L-Carnitine, Black Seed Oil, Saffron Extract, Quercetin, Garlic, and Berberine. The direct evidence for these interventions comes from meta-analyses, but the size and consistency of movement differed across interventions. Resveratrol and Ginger were unchanged in their direct measurements.

Rechecking was generally performed about 6.0 to 45.1 weeks after an intervention began, so changes should be understood within the timing used in the relevant trials rather than as an immediate response. These findings describe marker movement under study conditions and do not establish that any one option is appropriate for a particular person. When AST is being assessed in relation to a medical condition, interpretation is best discussed with a clinician.